ClinicalTrials.gg
Active, not recruitingNCT04398745DREAMM12Updated Jul 1, 2026Results posted

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

A Phase 1 interventional study of Belantamab mafodotin in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
28th of 49
36 · median 50
Started
2020
with 5 others
Phase 1
11 of 49
3 open now
Primary completion
2025-04
later than 8 of 34 live
Registered
9th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 28th largest by enrollment, is one of 6 that started in 2020, is one of 11 in phase 1, reaches primary completion later than 8 of the 34 other live ones, and was the 9th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation ) and have either normal or impaired renal functions. The study will consist of two parts: part 1 will include participants with normal/mildly impaired renal function and severe renal impairment and part 2 will include participants with end-stage renal disease (ESRD), where participants are either not undergoing or require hemodialysis. Participants will be administered belantamab mafodotin at a dose of 2.5 milligram per kilogram (mg/kg) intravenously once in three weeks (Q3W) dosing in Part 1. Based on the Part 1 Safety/Pharmacokinetic (PK) data, Part 2 participants will be administered the dose of either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose). Participants will be treated with belantamab mafodotin monotherapy until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. This study will include a screening phase, treatment phase, follow-up phase and a post analysis continued treatment (PACT) phase . The total duration of the study is approximately up to 48 months.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • DREAMM12
  • End-stage renal disease
  • Normal renal function
  • Renal impairment
  • Relapsed and/or refractory multiple myeloma
  • Belantamab mafodotin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are capable of giving signed which includes compliance with the requirements and restrictions listed in the Informed Consent Form.
  • Male and/or female participants must be 18 years of age or older, at the time of signing the informed consent. In Republic of Korea, participants must be 19 years of age or older at the time of signing informed consent.
  • (ECOG) performance status 0-2.
  • Participants with or cytologically confirmed diagnosis of MM, as defined in International Myeloma Working Group criteria: 1. Has undergone stem cell transplant (SCT) or is considered transplant-ineligible; 2. Has failed at least 2 prior lines of anti-myeloma treatments, including an immunomodulatory drug (example [e.g.], lenalidomide or pomalidomide) and a proteasome inhibitor (e.g., bortezomib, ixazomib or carfilzomib). In Republic of Korea, participants should also have disease after treatment with an anti-CD38 antibody, if accessible to patients, or other suitable local standard of care.
  • Participants have with at least one of the following: Serum M-protein >=0.5 grams per deciliter (g/dL) (>=5 grams per liter [g/L]); Urine M-protein >=200 milligrams (mg) per 24 hours (mg/24 h); and Serum free light chain (FLC) assay: Involved FLC level >=10 milligrams per deciliter (mg/dL) (>=100 milligrams per liter [mg/L]) and an abnormal serum FLC ratio (\<0.26 or >1.65).
  • Participants with a history of autologous SCT are eligible for study participation provided the following eligibility criteria are met: 1. Transplant was >100 days prior to study enrollment, 2. No active infection(s), and 3. Participant meets the remainder of the eligibility criteria outlined in this protocol.
  • Participants with adequate organ system functions as defined follows: >=1.0 x 10\^9 per liter (/L); >=7.0 g/dL or 4.9 millimoles per liter (mmol/L); >= 50 x 10\^9/L; Total \<=1.5 x (ULN) (Isolated bilirubin >=1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent [%]); \<=2.5 x ULN; iGFR, Group 1: normal/ mildly impaired >=60milliliter per minute (mL/min); Group 2: severe 15-29 mL/min; Group 3: ESRD (not on dialysis) \<15 mL/min; Group 4: ESRD (on dialysis) \<15 mL/min; and by echocardiograms >=40%.
  • Main additional inclusion criteria in Group 1 (matched control participants): Matched to at least one severely renal impaired participant by Baseline body weight (+/-20%) and Baseline albumin levels (+/-10%).
  • Female participants: use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of (WOCBP) OR is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, during the intervention period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive serum pregnancy test within 72 hours of dosing on Cycle 1 Day 1 and agree to use highly effective contraception during the study and for 4 months after the last dose of study medication. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Male participants: Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following from the time of first dose of study until 6 months after the last dose of study treatment to allow for clearance of any altered sperm: Refrain from donating sperm and either; Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; OR must agree to use a male condom even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year as when having sexual intercourse with a WOCBP (including pregnant females).

Exclusion criteria

Exclusion Criteria:

  • Participants with active plasma cell leukemia at the time of screening. Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, myeloma protein and skin changes), Waldenstroem Macroglobulinemia
  • Participants had a prior stem cell transplant. . Participants who have undergone a syngeneic bone marrow transplant will be allowed only if there is no history of, or no currently active graft-versus-host-diseases (GvHD).
  • Participant has received an drug within 14 days or 5 half-lives whichever is shorter, preceding the first dose of study drug. This includes prior treatment with a monoclonal antibody. The only exception is emergency use of a short course of systemic (equivalent to, or less than: dexamethasone 40 milligrams per day [mg/day] for a maximum of 4 days) before treatment.
  • Prior belantamab mafodotin therapy.
  • Participant has received a strong Organic-anion transporting polypeptide inhibitor within 14 days or 5 half-lives, whichever is shorter, preceding the first dose of study drug.
  • Systemic active infection requiring treatment.
  • Any unresolved toxicity >=Grade 2 from previous treatment except for alopecia, or peripheral neuropathy up to Grade 2.
  • Plasmapheresis within 7 days prior to the first dose of study drug. Screening laboratory values must be performed after last plasmapheresis.
  • Any major surgery within the last 4 weeks prior to Day 1 of Screening.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities except renal impairment) that could interfere with participant's safety, obtaining or compliance to the study procedures.
  • Evidence of active mucosal or internal bleeding.
  • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. (Stable chronic liver disease [(including Gilbert's syndrome or asymptomatic gallstones]) or hepatobiliary involvement of is acceptable if participant otherwise meets entry criteria)
  • Participants with previous or concurrent malignancies other than MM are excluded, unless the prior malignancy has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. (Participants with curatively treated non-melanoma skin cancer are allowed without a 2-year restriction)
  • Evidence of cardiovascular risk including any of the following: Evidence of current untreated arrhythmias, including clinically significant abnormalities such as second degree (Mobitz Type II) or third degree atrioventricular block; History of myocardial infarction (within prior 18 months), acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening; Class III or IV heart failure as defined by the functional classification system and uncontrolled hypertension.
  • Known immediate or delayed reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
  • Known infection, unless the participant can meet all of the following criteria: Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load \<400 copies/mL prior to first dose; CD4+ T-cell (CD4+) counts ≥350 cells/ L and no history of AIDS-defining opportunistic infections within the last 12 months
  • Participants with will be excluded unless the following criteria can be met: If the participant is hepatitis B core antibody (HbcAb) positive or hepatitis B surface antigen (HbsAg) negative, then hepatitis B virus (HBV) deoxyribonucleic acid (DNA) should be undectectable at the time of screening; If HbsAg+ at screening or \<=3 months prior to first dose of study treatment, then HBV DNA should be undetectable, highly effective antiviral treatment should be started ≥4 weeks prior to first dose of study treatment. Participants with cirrhosis are excluded.
  • Positive antibody test result or positive hepatitis C ribonucleic acid test result at Screening or within 3 months prior to first dose of study treatment unless the participant can meet the following criteria: RNA test negative and Successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a of at least 4 weeks prior to first dose.
  • Participants with renal impairment due to hepatic disease (hepatorenal syndrome).
  • Current corneal epithelial disease except for mild punctuate keratopathy.
  • Participant is a woman who is pregnant or breastfeeding.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Part 1: Participants with normal/mild impaired renal function

    Participants with normal or mildly impaired renal function (Normal: individual glomerular filtration rate \[iGFR\]: \>=90 milliliter per minute; Mild impairment: iGFR: 60-89 mL/min will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.

    Drug: Belantamab mafodotin

  • Experimental
    Part 1: Participants with severe renal impairment

    Participants with severely impaired renal function (iGFR: 15-29 mL/min) will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.

    Drug: Belantamab mafodotin

  • Experimental
    Part 2: Participants with ESRD (not on dialysis)

    Participants with ESRD (iGFR: \<15 mL/min) not on dialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.

    Drug: Belantamab mafodotin

  • Experimental
    Part 2: Participants with ESRD (on hemodialysis)

    Participants with ESRD (iGFR: \<15 mL/min) on hemodialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.

    Drug: Belantamab mafodotin

Interventions

  • Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.

    Also known as: GSK2857916

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  2. Part 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  3. Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.

    Time frame: End of infusion on C1D1 and C3D1

  4. Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  5. Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  6. Part 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  7. Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)

  8. Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  9. Part 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  10. Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.

    Time frame: End of infusion on C1D1 and C3D1

  11. Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  12. Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin total antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  13. Part 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  14. Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)

  15. Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  16. Part 1: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours. Outcome data are reported only for AUC over 0-168 hours.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15

  17. Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.

    Time frame: End of infusion on C1D1 and C3D1

  18. Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  19. Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  20. Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  21. Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  22. Part 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  23. Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC.

    Time frame: End of infusion on C1D1 and C3D1

  24. Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  25. Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  26. Part 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  27. Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)

  28. Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  29. Part 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  30. Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.

    Time frame: End of infusion on C1D1 and C3D1

  31. Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  32. Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  33. Part 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  34. Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)

    Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)

  35. Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  36. Part 2: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours. Outcome data are reported only for AUC over 0-168 hours.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15

  37. Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.

    Time frame: End of infusion on C1D1 and C3D1

  38. Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  39. Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

  40. Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

    Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.

Secondary outcomes

  1. Part 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

    Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value. The "0" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.

    Time frame: Baseline (Day 1) and up to approx. 236 weeks

  2. Part 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Heart Rate

    Heart rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and up to approx. 236 weeks

  3. Part 1 and Part 2: Number of Participants With Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 236 weeks

  4. Part 1 and Part 2: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline

    Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade was defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Baseline (Day 1) and up to approx. 236 weeks

  5. Part 1 and Part 2: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline

    Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade was defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Baseline (Day 1) and up to approx. 236 weeks

  6. Part 1 and Part 2: Change From Baseline (CFB) in Weight

    Physical examination parameter weight was assessed. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline

    Time frame: Baseline (Day 1) and up to approx. 236 weeks

  7. Part 1 and Part 2: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

    Urine samples were collected to assess occult blood and protein in urine by dipstick method. Data is presented as "No Change/Decreased" and "Any Increase" that includes Increase to TRACE, Increase to 1+, Increase to 2+ and Increase to 3+ indicating proportional concentrations in the urine sample. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Baseline (Day 1) and up to approx. 236 weeks

07

Results

Posted Jul 1, 2026

Participant flow

Participant flow — Overall Study
MilestonePart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Started109458
Safety population109458
Pharmacokinetic (pk) evaluable population88058
Completed87134
Not completed22324
Withdrew: Withdrawal by subject22201
Withdrew: Ongoing at time of analysis00123

Outcome measures

PrimaryPart 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · hour*microgram/millitre(h*ug/mL)
Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))
hour*microgram/millitre(h*ug/mL)Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 14021.3 ± 54.33704.7 ± 32.4
Cycle 36729.9 ± 32.14127.8 ± 30.4
PrimaryPart 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · h*ug/mL
Part 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)
h*ug/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 14379.2 ± 32.43683.1 ± 32.6
Cycle 37245.1 ± 42.23731.4 ± 17.8
PrimaryPart 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.

Time frame:
End of infusion on C1D1 and C3D1
Reported as:
Geometric mean · ug/mL
Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)
ug/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 1 Day 154.43 ± 31.545.66 ± 20.8
Cycle 3 Day 148.07 ± 39.432.70 ± 39.8
PrimaryPart 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ug/mL
Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)
ug/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 162.01 ± 38.447.62 ± 24.8
Cycle 374.18 ± 15.942.17 ± 58.0
PrimaryPart 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Median · Hour
Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)
HourPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 11.508 (0.650 to 2.083)3.000 (0.667 to 7.400)
Cycle 34.000 (2.000 to 8.000)2.083 (0.700 to 4.017)
PrimaryPart 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ug/mL
Part 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)
ug/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 11.954 ± 63.82.178 ± 39.9
Cycle 33.109 ± 34.13.011 ± 22.3
PrimaryPart 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
Reported as:
Median · Hour
Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)
HourPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 1396.3 (163.0 to 579.9)506.4 (503.3 to 528.4)
Cycle 3501.3 (334.8 to 697.7)482.5 (335.4 to 505.2)
PrimaryPart 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · h*ug/mL
Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)
h*ug/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 15591.2 ± 76.45443.7 ± 27.4
Cycle 39240.4 ± 18.97579.4 ± 35.1
PrimaryPart 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · h*ug/mL
Part 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)
h*ug/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 16543.6 ± 69.05217.0 ± 28.4
Cycle 39615.3 ± 19.07056.8 ± 32.9
PrimaryPart 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.

Time frame:
End of infusion on C1D1 and C3D1
Reported as:
Geometric mean · ug/mL
Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)
ug/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 1 Day 146.72 ± 35.029.61 ± 71.4
Cycle 3 Day 154.02 ± 15.136.83 ± 37.1
PrimaryPart 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ug/mL
Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)
ug/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 149.49 ± 30.339.33 ± 33.6
Cycle 354.63 ± 14.938.25 ± 32.0
PrimaryPart 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin total antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Median · Hour
Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)
HourPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 12.050 (0.583 to 4.067)2.008 (0.467 to 7.000)
Cycle 30.667 (0.650 to 2.000)2.017 (0.633 to 4.083)
PrimaryPart 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ug/mL
Part 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)
ug/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 18.785 ± 185.86.489 ± 103.2
Cycle 37.974 ± 22.89.359 ± 47.2
PrimaryPart 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
Reported as:
Median · Hour
Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)
HourPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 1346.9 (23.7 to 579.9)505.5 (334.3 to 528.4)
Cycle 3501.3 (334.8 to 697.7)482.5 (335.4 to 505.2)
PrimaryPart 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · h*ng/mL
Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))
h*ng/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 1127.3 ± 81.377.1 ± 53.1
Cycle 372.8 ± 21.840.8 ± 178.7
PrimaryPart 1: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours. Outcome data are reported only for AUC over 0-168 hours.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15
Reported as:
Geometric mean · h*ng/mL
Part 1: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
h*ng/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 1134.7 ± 99.875.2 ± 48.2
Cycle 361.2 ± 6.079.6 ± 39.3
PrimaryPart 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.

Time frame:
End of infusion on C1D1 and C3D1
Reported as:
Geometric mean · ng/mL
Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
ng/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 1 Day 10.84 ± 61.40.41 ± 78.2
Cycle 3 Day 10.54 ± 83.10.32 ± 174.1
PrimaryPart 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
ng/mLPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 11.63 ± 64.00.71 ± 48.2
Cycle 30.74 ± 19.20.50 ± 100.6
PrimaryPart 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Median · Hour
Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
HourPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 116.017 (0.917 to 92.600)23.400 (7.400 to 30.700)
Cycle 38.000 (0.583 to 22.167)23.967 (0.600 to 72.583)
PrimaryPart 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Median · Hour
Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
HourPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Cycle 1190.6 (163.0 to 359.5)167.7 (166.6 to 334.3)
Cycle 3334.8 (144.0 to 358.3)167.4 (45.7 to 335.4)
PrimaryPart 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · h*ug/mL
Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))
h*ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 14077.6 ± 19.73065.6 ± 66.2
Cycle 35773.6 ± 18.84798.2 ± 56.2
PrimaryPart 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · h*ug/mL
Part 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)
h*ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 13998.5 ± 18.43717.5 ± 61.3
Cycle 35764.2 ± 19.25633.7 ± 40.0
PrimaryPart 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC.

Time frame:
End of infusion on C1D1 and C3D1
Reported as:
Geometric mean · ug/mL
Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)
ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 1 Day 162.81 ± 64.540.30 ± 38.3
Cycle 3 Day 161.28 ± 37.446.38 ± 37.7
PrimaryPart 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ug/mL
Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)
ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 174.35 ± 50.653.50 ± 44.9
Cycle 366.61 ± 36.248.67 ± 33.8
PrimaryPart 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Median · Hour
Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)
HourPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 11.833 (0.683 to 4.083)1.958 (0.683 to 4.000)
Cycle 31.417 (0.500 to 2.117)2.050 (0.633 to 7.833)
PrimaryPart 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ug/mL
Part 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)
ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 11.756 ± 73.42.209 ± 104.4
Cycle 33.610 ± 54.82.530 ± 99.0
PrimaryPart 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
Reported as:
Median · Hour
Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)
HourPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 1551.3 (503.4 to 689.5)505.6 (72.3 to 720.7)
Cycle 3502.6 (500.6 to 529.4)503.0 (213.4 to 528.3)
PrimaryPart 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · h*ug/mL
Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)
h*ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 17099.5 ± 33.44018.0 ± 86.3
Cycle 39675.8 ± 8.18551.8 ± 79.0
PrimaryPart 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · h*ug/mL
Part 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)
h*ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 16798.4 ± 29.24798.2 ± 65.3
Cycle 39438.0 ± 9.010318.8 ± 63.8
PrimaryPart 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.

Time frame:
End of infusion on C1D1 and C3D1
Reported as:
Geometric mean · ug/mL
Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)
ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 1 Day 162.44 ± 53.037.24 ± 40.8
Cycle 3 Day 161.26 ± 41.138.80 ± 35.7
PrimaryPart 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ug/mL
Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)
ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 170.96 ± 46.741.11 ± 44.5
Cycle 370.67 ± 41.842.83 ± 40.4
PrimaryPart 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Median · Hour
Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)
HourPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 11.833 (0.667 to 2.050)2.025 (0.683 to 6.000)
Cycle 33.025 (0.783 to 7.033)2.050 (0.700 to 19.783)
PrimaryPart 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ug/mL
Part 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)
ug/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 15.899 ± 53.34.048 ± 130.9
Cycle 312.551 ± 35.97.846 ± 133.1
PrimaryPart 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)

Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
Reported as:
Median · Hour
Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)
HourPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 1551.3 (503.4 to 689.5)505.8 (72.3 to 720.7)
Cycle 3501.6 (359.9 to 529.4)503.0 (213.4 to 528.3)
PrimaryPart 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · h*ng/mL
Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))
h*ng/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 1264.5 ± 57.1147.7 ± 76.3
Cycle 3126.8 ± 42.1112.2 ± 53.6
PrimaryPart 2: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours. Outcome data are reported only for AUC over 0-168 hours.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15
Reported as:
Geometric mean · h*ng/mL
Part 2: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
h*ng/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 1248.0 ± 56.898.9 ± 46.1
Cycle 393.8 ± 38.5108.7 ± 70.5
PrimaryPart 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.

Time frame:
End of infusion on C1D1 and C3D1
Reported as:
Geometric mean · ng/mL
Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
ng/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 1 Day 10.66 ± 174.50.35 ± 113.1
Cycle 3 Day 10.44 ± 34.20.35 ± 71.8
PrimaryPart 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Geometric mean · ng/mL
Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
ng/mLPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 13.09 ± 46.10.93 ± 97.6
Cycle 30.83 ± 30.80.68 ± 51.9
PrimaryPart 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Median · Hour
Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
HourPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 123.833 (0.750 to 64.283)24.000 (22.017 to 50.700)
Cycle 324.333 (8.033 to 43.000)12.425 (4.000 to 22.667)
PrimaryPart 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.

Time frame:
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Reported as:
Median · Hour
Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
HourPart 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Cycle 1167.5 (160.4 to 328.8)335.5 (24.4 to 526.5)
Cycle 3347.3 (334.5 to 502.5)332.0 (213.4 to 504.8)
SecondaryPart 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value. The "0" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.

Time frame:
Baseline (Day 1) and up to approx. 236 weeks
Reported as:
Mean · Millimeters of mercury (mmHg)
Part 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Millimeters of mercury (mmHg)Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
DBP, Baseline (Day 1)72.5 ± 9.4570.9 ± 10.2077.8 ± 13.5764.4 ± 5.5574.8 ± 8.86
DBP, CFB to Cycle 1 Day 1, 15 MINS AFTER SOI-3.6 ± 8.02-4.2 ± 8.701.3 ± 2.871.6 ± 1.95-5.4 ± 7.04
DBP, CFB to Cycle 1 Day 1, WITHIN 15 MINS AFTER EOI0.2 ± 10.21-4.1 ± 7.03-2.8 ± 2.753.2 ± 2.59-7.6 ± 5.80
DBP, CFB to Cycle 1 Day 1, 1 HOUR AFTER EOI0.8 ± 12.06-2.9 ± 10.29-1.3 ± 5.192.0 ± 2.92-3.6 ± 6.09
DBP, CFB to Cycle 2 Day 1, PRE-INFUSION3.6 ± 8.23-5.6 ± 13.670.7 ± 0.588.4 ± 6.88-2.0 ± 9.57
DBP, CFB to Cycle 2 Day 1, WITHIN 15 MINS AFTER EOI-0.6 ± 7.88-5.5 ± 14.811.3 ± 2.5211.0 ± 7.62-6.6 ± 2.97
DBP, CFB to Cycle 3 Day 1, PRE-INFUSION-5.3 ± 11.150.8 ± 15.512.0 ± 1.419.5 ± 9.111.4 ± 10.15
DBP, CFB to Cycle 3 Day 1, WITHIN 15 MINS AFTER EOI-7.3 ± 9.461.0 ± 11.735.0 ± 1.415.0 ± 6.98-6.8 ± 12.07
DBP, CFB to Cycle 4 Day 1, PRE-INFUSION-1.0 ± 2.65-2.0 ± 17.441.5 ± 0.7113.8 ± 9.81-5.8 ± 9.41
DBP CFB to Cycle 4 Day 1, WITHIN 15 MINS AFTER EOI-2.3 ± 4.622.0 ± 17.693.0 ± 2.8313.5 ± 9.15-9.4 ± 7.40
DBP, CFB to Cycle 5 Day 1, PRE-INFUSION-3.7 ± 10.029.7 ± 31.012.0 ± NA6.0 ± 7.16-1.8 ± 7.63
DBP, CFB to Cycle 5 Day 1, WITHIN 15 MINS AFTER EOI-2.0 ± 10.4411.3 ± 23.463.0 ± NA7.0 ± 6.48-5.2 ± 3.27
DBP, CFB to Cycle 6 Day 1, PRE-INFUSION-2.3 ± 10.07-8.5 ± 16.26-2.0 ± NA13.3 ± 12.42-6.0 ± 5.15
DBP, CFB to Cycle 6 Day 1, WITHIN 15 MINS AFTER EOI0.0 ± 10.5811.5 ± 9.192.0 ± NA9.5 ± 12.40-7.3 ± 9.22
DBP, CFB to Cycle 7 Day 1, PRE-INFUSION0.7 ± 6.66-0.5 ± 4.952.0 ± NA17.5 ± 9.19-4.5 ± 4.95
DBP, CFB to Cycle 7 Day 1, WITHIN 15 MINS AFTER EOI2.0 ± 1.73-4.0 ± 7.070.0 ± NA20.0 ± 5.66-1.0 ± 1.41
DBP, CFB to Cycle 8 Day 1, PRE-INFUSION-1.0 ± 12.49-6.5 ± 13.441.0 ± NA14.0 ± NA-7.0 ± NA
DBP, CFB to Cycle 8 Day 1, WITHIN 15 MINS AFTER EOI-5.7 ± 7.02-6.5 ± 14.852.0 ± NA21.0 ± NA-1.0 ± NA
DBP, CFB to Cycle 9 Day 1, PRE-INFUSION-10.0 ± NA3.0 ± NA0.0 ± NA11.0 ± NA-3.0 ± NA
DBP, CFB to Cycle 9 Day 1, WITHIN 15 MINS AFTER EOI-7.0 ± NA4.0 ± NA3.0 ± NA25.0 ± NA-8.0 ± NA
DBP, CFB to Cycle 10 Day 1, PRE-INFUSION-10.0 ± NA7.0 ± NA4.0 ± NA17.0 ± NA-4.0 ± NA
DBP, CFB to Cycle 10 Day 1, WITHIN 15 MINS AFTER EOI-11.0 ± NA6.0 ± NA2.0 ± NA15.0 ± NA-7.0 ± NA
DBP, CFB to Cycle 11 Day 1, PRE-INFUSION-7.0 ± NA7.0 ± NA1.0 ± NA3.0 ± NA-1.0 ± NA
DBP, CFB to Cycle 11 Day 1, WITHIN 15 MINS AFTER EOI-7.0 ± NA5.0 ± NA5.0 ± NA2.0 ± NA-7.0 ± NA
DBP, CFB to Cycle 12 Day 1, PRE-INFUSION-13.0 ± NA1.0 ± NA-2.0 ± NA-4.0 ± NA6.0 ± NA
DBP, CFB to Cycle 12 Day 1, WITHIN 15 MINS AFTER EOI-12.0 ± NA3.0 ± NA2.0 ± NA-3.0 ± NA-2.0 ± NA
DBP, CFB to Cycle 13 Day 1, PRE-INFUSION-17.0 ± NA1.0 ± NA5.0 ± NA34.0 ± NA6.0 ± NA
DBP, CFB to Cycle 13 Day 1, WITHIN 15 MINS AFTER EOI-25.0 ± NA5.0 ± NA5.0 ± NA25.0 ± NA9.0 ± NA
DBP, CFB to Cycle 14 Day 1, PRE-INFUSION-15.0 ± NA0.0 ± NA-1.0 ± NA3.0 ± NA-4.0 ± NA
DBP, CFB to Cycle 14 Day 1, WITHIN 15 MINS AFTER EOI-20.0 ± NA-2.0 ± NA4.0 ± NA-3.0 ± NA-7.0 ± NA
DBP, CFB to Cycle 15 Day 1, PRE-INFUSION-5.0 ± NA0.0 ± NA-1.0 ± NA11.0 ± NA-7.0 ± NA
DBP, CFB to Cycle 15 Day 1, WITHIN 15 MINS AFTER EOI-6.0 ± NA-1.0 ± NA2.0 ± NA9.0 ± NA-15.0 ± NA
DBP, CFB to Cycle 16 Day 1, PRE-INFUSION-15.0 ± NA0.0 ± NA0.0 ± NA7.0 ± NA-8.0 ± NA
DBP, CFB to Cycle 16 Day 1, WITHIN 15 MINS AFTER EOI-10.0 ± NA2.0 ± NA5.0 ± NA2.0 ± NA-14.0 ± NA
DBP, CFB to Cycle 17 Day 1, PRE-INFUSION-5.0 ± NA1.0 ± NA2.0 ± NA0.0 ± NA-1.0 ± NA
DBP, CFB to Cycle 17 Day 1, WITHIN 15 MINS AFTER EOI-13.0 ± NA5.0 ± NA5.0 ± NA1.0 ± NA-4.0 ± NA
DBP, CFB to Cycle 18 Day 1, PRE-INFUSION-15.0 ± NA-2.0 ± NA1.0 ± NA7.0 ± NA-8.0 ± NA
DBP, CFB to Cycle 18 Day 1, WITHIN 15 MINS AFTER EOI-5.0 ± NA2.0 ± NA3.0 ± NA1.0 ± NA-5.0 ± NA
DBP, CFB to Cycle 19 Day 1, PRE-INFUSION-17.0 ± NA1.0 ± NA3.0 ± NA5.0 ± NA—
DBP, CFB to Cycle 19 Day 1, WITHIN 15 MINS AFTER EOI-15.0 ± NA6.0 ± NA6.0 ± NA9.0 ± NA—
DBP, CFB to Cycle 20 Day 1, PRE-INFUSION-12.0 ± NA——7.0 ± NA—
DBP, CFB to Cycle 20 Day 1, WITHIN 15 MINS AFTER EOI-15.0 ± NA——9.0 ± NA—
DBP, CFB to Cycle 21 Day 1, PRE-INFUSION-7.0 ± NA————
DBP, CFB to Cycle 21 Day 1, WITHIN 15 MINS AFTER EOI-7.0 ± NA————
DBP, CFB to Cycle 22 Day 1, PRE-INFUSION-10.0 ± NA————
DBP, CFB to Cycle 22 Day 1, WITHIN 15 MINS AFTER EOI-5.0 ± NA————
DBP, CFB to Cycle 23 Day 1, PRE-INFUSION-10.0 ± NA————
DBP, CFB to Cycle 23 Day 1, WITHIN 15 MINS AFTER EOI0.0 ± NA————
DBP, CFB to End of Treatment (Up to 236 weeks)-4.5 ± 10.79-2.0 ± 12.227.0 ± NA4.0 ± 9.90—
SBP, Baseline (Day 1)120.0 ± 6.99129.9 ± 21.32116.8 ± 8.42121.0 ± 5.29121.9 ± 17.50
SBP, CFB to Cycle 1 Day 1, 15 MINS AFTER SOI-2.8 ± 8.75-2.8 ± 17.043.8 ± 4.1915.8 ± 15.941.9 ± 1.95
SBP, CFB to Cycle 1 Day 1, WITHIN 15 MINS AFTER EOI0.9 ± 11.24-1.7 ± 14.945.0 ± 7.1210.0 ± 15.440.7 ± 3.73
SBP, CFB to Cycle 1 Day 1, 1 HOUR AFTER EOI-0.6 ± 11.04-3.1 ± 18.616.0 ± 6.0611.4 ± 14.362.8 ± 5.63
SBP, CFB to Cycle 2 Day 1, PRE-INFUSION1.6 ± 14.43-2.0 ± 19.763.7 ± 3.0627.0 ± 24.279.0 ± 17.47
SBP, CFB to Cycle 2 Day 1, WITHIN 15 MINS AFTER EOI-0.9 ± 5.46-4.1 ± 16.213.7 ± 1.5322.0 ± 19.692.8 ± 7.29
SBP, CFB to Cycle 3 Day 1, PRE-INFUSION-5.8 ± 4.992.4 ± 16.386.5 ± 6.3622.8 ± 16.8810.0 ± 11.72
SBP, CFB to Cycle 3 Day 1, WITHIN 15 MINS AFTER EOI-3.8 ± 5.44-0.6 ± 19.962.5 ± 2.1224.5 ± 18.529.0 ± 16.84
SBP, CFB to Cycle 4 Day 1, PRE-INFUSION-0.3 ± 2.52-9.0 ± 22.340.0 ± 2.8310.0 ± 15.817.0 ± 9.70
SBP, CFB to Cycle 4 Day 1, WITHIN 15 MINS AFTER EOI-6.0 ± 4.36-9.0 ± 25.71-0.5 ± 9.1925.5 ± 25.284.0 ± 3.94
SBP, CFB to Cycle 5 Day 1, PRE-INFUSION0.3 ± 5.779.7 ± 24.117.0 ± NA11.8 ± 16.9413.8 ± 13.48
SBP, CFB to Cycle 5 Day 1, WITHIN 15 MINS AFTER EOI5.7 ± 10.69-0.7 ± 34.246.0 ± NA13.3 ± 17.738.6 ± 10.14
SBP, CFB to Cycle 6 Day 1, PRE-INFUSION-4.3 ± 1.53-10.0 ± 12.738.0 ± NA9.3 ± 25.400.6 ± 15.52
SBP, CFB to Cycle 6 Day 1, WITHIN 15 MINS AFTER EOI4.7 ± 12.42-11.0 ± 15.566.0 ± NA9.8 ± 25.6212.3 ± 13.72
SBP, CFB to Cycle 7 Day 1, PRE-INFUSION3.3 ± 10.12-6.0 ± 2.836.0 ± NA23.5 ± 30.41-7.0 ± 1.41
SBP, CFB to Cycle 7 Day 1, WITHIN 15 MINS AFTER EOI3.0 ± 8.72-20.5 ± 26.1610.0 ± NA26.0 ± 48.08-9.0 ± 11.31
SBP, CFB to Cycle 8 Day 1, PRE-INFUSION-2.3 ± 4.04-8.5 ± 12.021.0 ± NA30.0 ± NA0.0 ± NA
SBP, CFB to Cycle 8 Day 1, WITHIN 15 MINS AFTER EOI-6.3 ± 5.86-11.0 ± 19.800.0 ± NA75.0 ± NA-1.0 ± NA
SBP, CFB to Cycle 9 Day 1, PRE-INFUSION-3.0 ± NA3.0 ± NA3.0 ± NA54.0 ± NA14.0 ± NA
SBP, CFB to Cycle 9 Day 1, WITHIN 15 MINS AFTER EOI3.0 ± NA5.0 ± NA5.0 ± NA80.0 ± NA4.0 ± NA
SBP, CFB to Cycle 10 Day 1, PRE-INFUSION-3.0 ± NA5.0 ± NA9.0 ± NA56.0 ± NA0.0 ± NA
SBP, CFB to Cycle 10 Day 1, WITHIN 15 MINS AFTER EOI-2.0 ± NA3.0 ± NA12.0 ± NA52.0 ± NA4.0 ± NA
SBP, CFB to Cycle 11 Day 1, PRE-INFUSION-13.0 ± NA-4.0 ± NA2.0 ± NA18.0 ± NA20.0 ± NA
SBP, CFB to Cycle 11 Day 1, WITHIN 15 MINS AFTER EOI-5.0 ± NA0.0 ± NA3.0 ± NA30.0 ± NA15.0 ± NA
SBP, CFB to Cycle 12 Day 1, PRE-INFUSION-13.0 ± NA5.0 ± NA8.0 ± NA15.0 ± NA5.0 ± NA
SBP, CFB to Cycle 12 Day 1, WITHIN 15 MINS AFTER EOI-8.0 ± NA4.0 ± NA12.0 ± NA17.0 ± NA3.0 ± NA
SBP, CFB to Cycle 13 Day 1, PRE-INFUSION5.0 ± NA-2.0 ± NA7.0 ± NA42.0 ± NA6.0 ± NA
SBP, CFB to Cycle 13 Day 1, WITHIN 15 MINS AFTER EOI-5.0 ± NA-1.0 ± NA6.0 ± NA44.0 ± NA4.0 ± NA
SBP, CFB to Cycle 14 Day 1, PRE-INFUSION-3.0 ± NA-4.0 ± NA12.0 ± NA19.0 ± NA0.0 ± NA
SBP, CFB to Cycle 14 Day 1, WITHIN 15 MINS AFTER EOI0.0 ± NA0.0 ± NA13.0 ± NA18.0 ± NA4.0 ± NA
SBP, CFB to Cycle 15 Day 1, PRE-INFUSION7.0 ± NA5.0 ± NA7.0 ± NA41.0 ± NA0.0 ± NA
SBP, CFB to Cycle 15 Day 1, WITHIN 15 MINS AFTER EOI6.0 ± NA4.0 ± NA9.0 ± NA42.0 ± NA4.0 ± NA
SBP, CFB to Cycle 16 Day 1, PRE-INFUSION-3.0 ± NA4.0 ± NA6.0 ± NA41.0 ± NA-6.0 ± NA
SBP, CFB to Cycle 16 Day 1, WITHIN 15 MINS AFTER EOI2.0 ± NA6.0 ± NA9.0 ± NA31.0 ± NA4.0 ± NA
SBP, Cycle 17 Day 1, PRE-INFUSION-3.0 ± NA4.0 ± NA3.0 ± NA23.0 ± NA25.0 ± NA
SBP, Cycle 17 Day 1, WITHIN 15 MINS AFTER EOI-5.0 ± NA2.0 ± NA8.0 ± NA35.0 ± NA23.0 ± NA
SBP, CFB to Cycle 18 Day 1, PRE-INFUSION-3.0 ± NA-3.0 ± NA4.0 ± NA48.0 ± NA0.0 ± NA
SBP, CFB to Cycle 18 Day 1, WITHIN 15 MINS AFTER EOI-3.0 ± NA1.0 ± NA8.0 ± NA33.0 ± NA15.0 ± NA
SBP, CFB to Cycle 19 Day 1, PRE-INFUSION-5.0 ± NA6.0 ± NA2.0 ± NA28.0 ± NA—
SBP, CFB to Cycle 19 Day 1, WITHIN 15 MINS AFTER EOI-3.0 ± NA8.0 ± NA7.0 ± NA48.0 ± NA—
SBP, CFB to Cycle 20 Day 1, PRE-INFUSION4.0 ± NA——50.0 ± NA—
SBP, CFB to Cycle 20 Day 1, WITHIN 15 MINS AFTER EOI3.0 ± NA——48.0 ± NA—
SBP, CFB to Cycle 21 Day 1, PRE-INFUSION26.0 ± NA————
SBP, CFB to Cycle 21 Day 1, WITHIN 15 MINS AFTER EOI12.0 ± NA————
SBP, CFB to Cycle 22 Day 1, PRE-INFUSION-1.0 ± NA————
SBP, CFB to Cycle 22 Day 1, WITHIN 15 MINS AFTER EOI12.0 ± NA————
SBP, CFB to Cycle 23 Day 1, PRE-INFUSION11.0 ± NA————
SBP, CFB to Cycle 23 Day 1, WITHIN 15 MINS AFTER EOI9.0 ± NA————
SBP, CFB to End of Treatment (Up to 236 weeks)-2.8 ± 12.79-5.9 ± 15.391.0 ± NA31.0 ± 29.70—
SecondaryPart 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Heart Rate

Heart rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and up to approx. 236 weeks
Reported as:
Mean · Beats per minute
Part 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Heart Rate
Beats per minutePart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Baseline (Day 1)77.2 ± 14.6774.9 ± 15.3471.8 ± 4.5769.0 ± 11.0567.4 ± 6.78
CFB to Cycle 1 Day 1, 15 MINS AFTER SOI-1.3 ± 3.65-4.0 ± 6.222.0 ± 2.941.2 ± 5.452.3 ± 2.87
CFB to Cycle 1 Day 1, WITHIN 15 MINS AFTER EOI-1.1 ± 6.03-0.9 ± 4.044.3 ± 7.411.8 ± 7.192.1 ± 2.27
CFB to Cycle 1 Day 1, 1 HOUR AFTER EOI3.0 ± 5.72-1.0 ± 4.304.8 ± 10.37-1.2 ± 6.910.9 ± 3.56
CFB to Cycle 2 Day 1, PRE-INFUSION1.2 ± 10.03-5.0 ± 5.501.3 ± 9.29-0.2 ± 9.151.2 ± 7.96
CFB to Cycle 2 Day 1, WITHIN 15 MINS AFTER EOI-2.2 ± 13.34-3.8 ± 7.67-0.3 ± 7.37-1.0 ± 10.496.4 ± 8.53
CFB to Cycle 3 Day 1, PRE-INFUSION-12.3 ± 7.85-2.4 ± 11.487.5 ± 9.195.3 ± 19.052.9 ± 9.12
CFB to Cycle 3 Day 1, WITHIN 15 MINS AFTER EOI-9.0 ± 9.450.6 ± 13.504.5 ± 6.36-5.0 ± 7.795.8 ± 10.23
CFB to Cycle 4 Day 1, PRE-INFUSION0.0 ± 6.00-12.3 ± 25.745.5 ± 14.85-6.5 ± 11.474.0 ± 5.37
CFB to Cycle 4 Day 1, WITHIN 15 MINS AFTER EOI-1.3 ± 9.07-15.7 ± 22.941.0 ± 11.31-8.5 ± 12.876.0 ± 5.52
CFB to Cycle 5 Day 1, PRE-INFUSION-3.7 ± 19.14-3.3 ± 9.290.0 ± NA-5.8 ± 8.965.7 ± 10.65
CFB to Cycle 5 Day 1, WITHIN 15 MINS AFTER EOI-6.0 ± 11.14-5.7 ± 9.07-2.0 ± NA-5.0 ± 9.244.2 ± 3.83
CFB to Cycle 6 Day 1, PRE-INFUSION-6.0 ± 13.118.5 ± 7.78-3.0 ± NA-0.3 ± 7.416.2 ± 7.92
CFB to Cycle 6 Day 1, WITHIN 15 MINS AFTER EOI-7.7 ± 9.613.5 ± 3.54-4.0 ± NA1.8 ± 7.274.5 ± 7.42
CFB to Cycle 7 Day 1, PRE-INFUSION-5.3 ± 7.093.5 ± 2.12-8.0 ± NA-1.5 ± 6.365.5 ± 0.71
CFB to Cycle 7 Day 1, WITHIN 15 MINS AFTER EOI-8.3 ± 12.862.5 ± 2.12-3.0 ± NA2.0 ± 9.906.5 ± 0.71
CFB to Cycle 8 Day 1, PRE-INFUSION-9.7 ± 12.5814.5 ± 16.26-4.0 ± NA-17.0 ± NA6.0 ± NA
CFB to Cycle 8 Day 1, WITHIN 15 MINS AFTER EOI-11.3 ± 9.2915.0 ± 18.38-2.0 ± NA-18.0 ± NA8.0 ± NA
CFB to Cycle 9 Day 1, PRE-INFUSION-20.0 ± NA5.0 ± NA-8.0 ± NA-22.0 ± NA10.0 ± NA
CFB to Cycle 9 Day 1, WITHIN 15 MINS AFTER EOI-22.0 ± NA4.0 ± NA-10.0 ± NA-17.0 ± NA12.0 ± NA
CFB to Cycle 10 Day 1, PRE-INFUSION-23.0 ± NA6.0 ± NA-5.0 ± NA-17.0 ± NA5.0 ± NA
CFB to Cycle 10 Day 1, WITHIN 15 MINS AFTER EOI-24.0 ± NA4.0 ± NA-2.0 ± NA-16.0 ± NA0.0 ± NA
CFB to Cycle 11 Day 1, PRE-INFUSION-9.0 ± NA7.0 ± NA-4.0 ± NA-12.0 ± NA0.0 ± NA
CFB to Cycle 11 Day 1, WITHIN 15 MINS AFTER EOI-20.0 ± NA5.0 ± NA-8.0 ± NA-10.0 ± NA1.0 ± NA
CFB to Cycle 12 Day 1, PRE-INFUSION-10.0 ± NA2.0 ± NA1.0 ± NA-2.0 ± NA4.0 ± NA
CFB to Cycle 12 Day 1, WITHIN 15 MINS AFTER EOI-9.0 ± NA7.0 ± NA2.0 ± NA-5.0 ± NA2.0 ± NA
CFB to Cycle 13 Day 1, PRE-INFUSION-22.0 ± NA3.0 ± NA-2.0 ± NA-6.0 ± NA4.0 ± NA
CFB to Cycle 13 Day 1, WITHIN 15 MINS AFTER EOI-33.0 ± NA4.0 ± NA1.0 ± NA2.0 ± NA2.0 ± NA
CFB to Cycle 14 Day 1, PRE-INFUSION-28.0 ± NA3.0 ± NA-8.0 ± NA-6.0 ± NA6.0 ± NA
CFB to Cycle 14 Day 1, WITHIN 15 MINS AFTER EOI-30.0 ± NA4.0 ± NA-6.0 ± NA-5.0 ± NA-2.0 ± NA
CFB to Cycle 15 Day 1, PRE-INFUSION-24.0 ± NA10.0 ± NA0.0 ± NA-15.0 ± NA0.0 ± NA
CFB to Cycle 15 Day 1, WITHIN 15 MINS AFTER EOI-24.0 ± NA8.0 ± NA-1.0 ± NA-14.0 ± NA-1.0 ± NA
CFB to Cycle 16 Day 1, PRE-INFUSION-30.0 ± NA6.0 ± NA-5.0 ± NA-17.0 ± NA-2.0 ± NA
CFB to Cycle 16 Day 1, WITHIN 15 MINS AFTER EOI-28.0 ± NA2.0 ± NA-3.0 ± NA-11.0 ± NA2.0 ± NA
CFB to Cycle 17 Day 1, PRE-INFUSION-30.0 ± NA3.0 ± NA-2.0 ± NA-3.0 ± NA0.0 ± NA
CFB to Cycle 17 Day 1, WITHIN 15 MINS AFTER EOI-28.0 ± NA2.0 ± NA0.0 ± NA-3.0 ± NA7.0 ± NA
CFB to Cycle 18 Day 1, PRE-INFUSION-40.0 ± NA5.0 ± NA-1.0 ± NA-9.0 ± NA-4.0 ± NA
CFB to Cycle 18 Day 1, WITHIN 15 MINS AFTER EOI-38.0 ± NA6.0 ± NA-2.0 ± NA-1.0 ± NA11.0 ± NA
CFB to Cycle 19 Day 1, PRE-INFUSION-38.0 ± NA6.0 ± NA3.0 ± NA-8.0 ± NA—
CFB to Cycle 19 Day 1, WITHIN 15 MINS AFTER EOI-40.0 ± NA9.0 ± NA2.0 ± NA-2.0 ± NA—
CFB to Cycle 20 Day 1, PRE-INFUSION-20.0 ± NA——1.0 ± NA—
CFB to Cycle 20 Day 1, WITHIN 15 MINS AFTER EOI-17.0 ± NA——-2.0 ± NA—
CFB to Cycle 21 Day 1, PRE-INFUSION-16.0 ± NA————
CFB to Cycle 21 Day 1, WITHIN 15 MINS AFTER EOI-34.0 ± NA————
CFB to Cycle 22 Day 1, PRE-INFUSION-23.0 ± NA————
CFB to Cycle 22 Day 1, WITHIN 15 MINS AFTER EOI-18.0 ± NA————
CFB to Cycle 23 Day 1, PRE-INFUSION-19.0 ± NA————
CFB to Cycle 23 Day 1, WITHIN 15 MINS AFTER EOI-29.0 ± NA————
CFB to End of Treatment (Up to 236 weeks)8.8 ± 26.0814.1 ± 10.613.0 ± NA8.0 ± 22.63—
SecondaryPart 1 and Part 2: Number of Participants With Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 236 weeks
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Adverse Events (AEs)
ParticipantsPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Part 1 and Part 2: Number of Participants With Adverse Events (AEs)109358
SecondaryPart 1 and Part 2: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline

Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade was defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Baseline (Day 1) and up to approx. 236 weeks
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline
ParticipantsPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Anemia, Increase to Grade 322123
Anemia, Increase to Grade 400000
Eosinophilia, Increase to Grade 300000
Eosinophilia, Increase to Grade 400000
Hemoglobin increased, Increase to Grade 300001
Hemoglobin increased, Increase to Grade 400000
Leukocytosis, Increase to Grade 300000
Leukocytosis, Increase to Grade 400000
Lymphocyte count decreased, Increase to Grade 321021
Lymphocyte count decreased, Increase to Grade 400000
Lymphocyte count increased, Increase to Grade 300010
Lymphocyte count increased, Increase to Grade 400000
Neutrophil count decreased, Increase to Grade 310000
Neutrophil count decreased, Increase to Grade 400001
Platelet count decreased, Increase to Grade 321012
Platelet count decreased, Increase to Grade 422000
White blood cell decreased, Increase to Grade 311001
White blood cell decreased, Increase to Grade 400000
SecondaryPart 1 and Part 2: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline

Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade was defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Baseline (Day 1) and up to approx. 236 weeks
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline
ParticipantsPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Alanine aminotransferase (ALT) increased, Increase to Grade 300000
ALT increased, Increase to Grade 400000
Alkaline phosphatase (ALP) increased, Increase to Grade 300000
ALP increased, Increase to Grade 400000
Aspartate aminotransferase (AST) increased, Increase to Grade 300000
AST increased, Increase to Grade 400000
Blood bilirubin increased, Increase to Grade 300000
Blood bilirubin increased, Increase to Grade 400000
Blood lactate dehydrogenase increased, Increase to Grade 300000
Blood lactate dehydrogenase increased, Increase to Grade 400000
Creatine kinase (CPK) increased, Increase to Grade 300000
CPK increased, Increase to Grade 400000
Chronic Kidney Disease eGFR, Increase to Grade 301000
Chronic Kidney Disease eGFR, Increase to Grade 401001
Chronic Kidney Disease iGFR, Increase to Grade 300000
Chronic Kidney Disease iGFR, Increase to Grade 410001
Creatinine increased, Increase to Grade 300000
Creatinine increased, Increase to Grade 400000
Gamma-glutamyltransferase (GGT) increased, Increase to Grade 300000
GGT increased, Increase to Grade 400000
Hypercalcemia, Increase to Grade 300000
Hypercalcemia, Increase to Grade 400000
Hyperkalemia, Increase to Grade 300001
Hyperkalemia, Increase to Grade 400000
Hypermagnesemia, Increase to Grade 300000
Hypermagnesemia, Increase to Grade 400000
Hypernatremia, Increase to Grade 300000
Hypernatremia, Increase to Grade 400000
Hypoalbuminemia, Increase to Grade 310000
Hypoalbuminemia, Increase to Grade 400000
Hypocalcemia, Increase to Grade 300000
Hypocalcemia, Increase to Grade 401000
Hypoglycemia, Increase to Grade 300000
Hypoglycemia, Increase to Grade 400001
Hypomagnesemia, Increase to Grade 300010
Hypomagnesemia, Increase to Grade 400000
SecondaryPart 1 and Part 2: Change From Baseline (CFB) in Weight

Physical examination parameter weight was assessed. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline

Time frame:
Baseline (Day 1) and up to approx. 236 weeks
Reported as:
Mean · Kilogram (Kg)
Part 1 and Part 2: Change From Baseline (CFB) in Weight
Kilogram (Kg)Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Baseline (Day 1)73.44 ± 19.61968.92 ± 12.14384.03 ± 28.34961.34 ± 15.53668.41 ± 20.296
CFB to Cycle 2 Day 10.51 ± 2.7500.34 ± 0.870-0.43 ± 0.929-0.22 ± 1.7940.17 ± 0.695
CFB to Cycle 3 Day 10.38 ± 0.6240.52 ± 1.099-0.15 ± 0.4950.63 ± 1.040-0.89 ± 3.302
CFB to Cycle 4 Day 1-0.80 ± 3.8631.10 ± 0.173-0.75 ± 1.0611.18 ± 1.195-0.17 ± 2.967
CFB to Cycle 5 Day 10.07 ± 2.6631.60 ± 0.6560.50 ± NA1.43 ± 1.3380.47 ± 4.575
CFB to Cycle 6 Day 11.33 ± 3.8891.45 ± 0.778-0.80 ± NA1.88 ± 4.785-2.88 ± 3.664
CFB to Cycle 7 Day 10.13 ± 2.6952.15 ± 0.212-1.20 ± NA1.95 ± 1.344-2.20 ± 2.970
CFB to Cycle 8 Day 10.10 ± 3.843-0.10 ± 3.394-1.40 ± NA3.00 ± NA0.00 ± NA
CFB to Cycle 9 Day 15.00 ± NA2.50 ± NA-1.50 ± NA3.50 ± NA0.20 ± NA
CFB to Cycle 10 Day 13.30 ± NA2.60 ± NA-1.60 ± NA3.60 ± NA0.00 ± NA
CFB to Cycle 11 Day 13.40 ± NA2.50 ± NA-1.70 ± NA3.00 ± NA-0.40 ± NA
CFB to Cycle 12 Day 13.30 ± NA2.30 ± NA-1.70 ± NA4.50 ± NA-0.40 ± NA
CFB to Cycle 13 Day 12.90 ± NA2.40 ± NA-1.80 ± NA4.80 ± NA-0.40 ± NA
CFB to Cycle 14 Day 15.50 ± NA2.50 ± NA-1.60 ± NA3.00 ± NA-0.70 ± NA
CFB to Cycle 15 Day 16.50 ± NA2.40 ± NA-1.40 ± NA2.00 ± NA0.00 ± NA
CFB to Cycle 16 Day 14.80 ± NA2.70 ± NA-1.50 ± NA1.30 ± NA0.20 ± NA
CFB to Cycle 17 Day 13.00 ± NA2.10 ± NA-1.60 ± NA1.60 ± NA-0.20 ± NA
CFB to Cycle 18 Day 12.00 ± NA2.00 ± NA-1.80 ± NA1.00 ± NA0.30 ± NA
CFB to Cycle 19 Day 11.60 ± NA2.30 ± NA-1.70 ± NA0.70 ± NA—
CFB to Cycle 20 Day 10.70 ± NA——0.90 ± NA—
CFB to Cycle 21 Day 11.00 ± NA————
CFB to Cycle 22 Day 11.00 ± NA————
CFB to Cycle 23 Day 12.80 ± NA————
CFB to Week 07—2.50 ± NA———
CFB to Week 10—0.00 ± NA———
CFB to Week 13—-3.00 ± NA———
CFB to End of Treatment (Up to 236 weeks)-1.38 ± 4.8860.47 ± 2.8560.00 ± NA-0.80 ± 1.273—
SecondaryPart 1 and Part 2: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

Urine samples were collected to assess occult blood and protein in urine by dipstick method. Data is presented as "No Change/Decreased" and "Any Increase" that includes Increase to TRACE, Increase to 1+, Increase to 2+ and Increase to 3+ indicating proportional concentrations in the urine sample. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Baseline (Day 1) and up to approx. 236 weeks
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
ParticipantsPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Occult Blood — No Change/Decreased00000
Occult Blood — Any Increase01000
Protein — No Change/Decreased35242
Protein — Any Increase23010

Adverse events

Collected over All-cause mortality, non-serious adverse events (non-SAEs) and SAEs were collected up to approximately 236 weeks. The results presented are based on the data cut-off date of 21 April 2025. Additional safety results will be provided within one year of study completion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)2/10 (20%)4/10 (40%)10/10 (100%)
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)3/9 (33.3%)4/9 (44.4%)9/9 (100%)
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)0/4 (0%)2/4 (50%)3/4 (75%)
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)1/5 (20%)3/5 (60%)5/5 (100%)
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)3/8 (37.5%)4/8 (50%)8/8 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
PneumoniaInfections and infestations0/101/90/41/52/8
Acute kidney injuryRenal and urinary disorders0/101/91/40/50/8
FallInjury, poisoning and procedural complications0/100/91/40/50/8
FractureInjury, poisoning and procedural complications0/100/91/40/50/8
Chronic kidney diseaseRenal and urinary disorders0/102/90/40/50/8
COVID-19Infections and infestations1/100/90/41/50/8
Sudden deathGeneral disorders0/100/90/41/50/8
Humerus fractureInjury, poisoning and procedural complications0/100/90/41/50/8
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/100/90/41/50/8
Bone painMusculoskeletal and connective tissue disorders0/100/90/41/50/8
Most frequent other events
Showing 10 of 131
Most frequent other events
EventPart 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
PyrexiaGeneral disorders2/101/91/44/52/8
Vision blurredEye disorders6/105/91/43/53/8
Dry eyeEye disorders5/104/92/40/54/8
Eye irritationEye disorders5/103/91/41/53/8
Foreign body sensation in eyesEye disorders5/102/91/41/52/8
ChillsGeneral disorders0/100/92/40/50/8
HypercalcaemiaMetabolism and nutrition disorders1/100/92/40/50/8
Eye painEye disorders4/101/90/41/51/8
AnaemiaBlood and lymphatic system disorders4/101/91/42/52/8
Alanine aminotransferase increasedInvestigations1/100/90/42/51/8

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)Total
Mean60.3 ± 8.2174.6 ± 6.1167.5 ± 10.7981.4 ± 5.2270.9 ± 6.8369.9 ± 10.00
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)Total
Female4131211
Male6814625
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)Total
American Indian or Alaska Native000000
Asian5203111
Native Hawaiian or Other Pacific Islander000000
Black or African American120047
White4542318
More than one race000000
Unknown or Not Reported000000
08

Study locations

4 sites
  • GSK Investigational Site
    Athens, 10676, Greece
  • GSK Investigational Site
    Athens, 11528, Greece
  • GSK Investigational Site
    Busan, 49241, South Korea
  • GSK Investigational Site
    Seoul, 06591, South Korea
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Apr 2025, 54 months.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 54 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2020
First posted
May 21, 2020
StartActual
Oct 9, 2020
Primary completionActual
Apr 21, 2025
CompletionEst.
Mar 11, 2027
Results first posted
Jul 1, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04398745
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 21, 2020
Start date
Oct 9, 2020
Primary completion
Apr 21, 2025
Completion
Mar 11, 2027 (estimated)
Results posted
Jul 1, 2026
Last update
Jul 1, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion